AB7356
Anti-von Willebrand Factor Antibody
Chemicon®, from rabbit
Synonym(s):
Factor VIII Related Antigen
Sign Into View Organizational & Contract Pricing
All Photos(8)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human, rat, mouse
packaging
antibody small pack of 25 μg
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry: suitable (paraffin)
NCBI accession no.
UniProt accession no.
shipped in
ambient
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... F8(302470) , VWF(7450)
rat ... F8(302470)
General description
This Anti-von Willebrand Factor Antibody is validated for use in ELISA, Immunohistochemistry (IHC) for the detection of von Willebrand Factor.
von Willebrand factor (UniProt: P04275; also known as vWF) is encoded by the VWF (also known as F8VWF) gene (Gene ID:7450) in human. vWF is a multimeric plasma glycoprotein that is synthesized by endothelial cells and plays an important in the maintenance of hemostasis. It is synthesized with a signal peptide (aa 1-22), which is subsequently cleaved off in the mature form. vWF is known to promote adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. vWF also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Mutations in VWF gene are linked to von Willebrand diseases 1-3 that are common hemorrhagic disorders caused by impaired platelet aggregation. Two isoforms of vWF have been described that are produced by alternative splicing.
Specificity
AB7356 is specific for vWF by ELISA against the human protein and by immunohistochemistry. The antibody is reactive in paraffin embedded tissues on human, rat, and mouse. Other species not tested. Antibody has not been evaluated by western blot analysis for reactivity to vWF.
Immunogen
Human von Willebrand Factor purified from plasma.
Application
Anti-von Willebrand Factor, Cat. No. AB7356, is a rabbit polyclonal antibody that detects von Willebrand Factor and has been tested for use in ELISA, Immunohistochemistry, and Western Blotting.
Immunohistochemistry Analysis: A representative lot detected von Willebrand Factor in Immunohistochemistry applications.
ELISA Analysis: A representative lot detected von Willebrand Factor in ELISA applications.
Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected von Willebrand Factor in human cerebral cortex, mouse hippocampus, rat cerebellum and human tonsil tissue sections.
ELISA Analysis: A representative lot detected von Willebrand Factor in ELISA applications.
Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected von Willebrand Factor in human cerebral cortex, mouse hippocampus, rat cerebellum and human tonsil tissue sections.
Research Category
Cell Structure
Cell Structure
Research Sub Category
ECM Proteins
ECM Proteins
Quality
Immunohistochemistry(paraffin):
Representative images from a previous lot.
Rabbit anti-vWF (AB7356) staining of Human Cerebral Cortex. Tissue pretreated with Citrate Buffer, ph 6.0, anti-vWF at 20 μg/mL, IHC-Select Detection with HRP-DAB.
Representative images from a previous lot.
Rabbit anti-vWF (AB7356) staining of Human Cerebral Cortex. Tissue pretreated with Citrate Buffer, ph 6.0, anti-vWF at 20 μg/mL, IHC-Select Detection with HRP-DAB.
Target description
250 kDa
Physical form
Format: Purified
Protein A purified
Purified rabbit immunoglobulin in buffer containing 0.02 M PBS pH 7.6, 0.25 M NaCl with 0.1% sodium azide.
Storage and Stability
Stable for 1 year at 2-8ºC from date of receipt.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Antagonizing the ?v ?3 integrin inhibits angiogenesis and impairs woven but not lamellar bone formation induced by mechanical loading.
Tomlinson, RE; Schmieder, AH; Quirk, JD; Lanza, GM; Silva, MJ
Journal of Bone and Mineral Research null
Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.
Moaveni, DK; Lynch, EM; Luke, C; Sood, V; Upchurch, GR; Wakefield, TW; Henke, PK
Journal of Vascular Surgery null
John-Michael Arpino et al.
Circulation research, 120(9), 1453-1465 (2017-02-09)
Angiogenesis occurs after ischemic injury to skeletal muscle, and enhancing this response has been a therapeutic goal. However, to appropriately deliver oxygen, a precisely organized and exquisitely responsive microcirculation must form. Whether these network attributes exist in a regenerated microcirculation
Gage Brummer et al.
Molecular cancer research : MCR, 16(2), 296-308 (2017-11-15)
Ductal carcinoma in situ (DCIS) is the most common form of breast cancer, with 50,000 cases diagnosed every year in the United States. Overtreatment and undertreatment remain significant clinical challenges in patient care. Identifying key mechanisms associated with DCIS progression
Aleksander Skardal et al.
Stem cells translational medicine, 1(11), 792-802 (2012-12-01)
Stem cells obtained from amniotic fluid show high proliferative capacity in culture and multilineage differentiation potential. Because of the lack of significant immunogenicity and the ability of the amniotic fluid-derived stem (AFS) cells to modulate the inflammatory response, we investigated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service